Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

scientific article published in August 2002

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID12149202

P50authorClara D. BloomfieldQ4793409
Richard A. LarsonQ41899936
Charles A SchifferQ88557115
Jonathan E KolitzQ90696849
Michael A CaligiuriQ97333782
Bayard L PowellQ114413078
John AnastasiQ114529746
P2093author name stringMaria R Baer
Stephen L George
Richard K Dodge
Hans Minderman
Kieran L O'Loughlin
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectpatientQ181600
acute myeloid leukemiaQ264118
multiple drug resistanceQ643839
leukemiaQ29496
P304page(s)1224-1232
P577publication date2002-08-01
P1433published inBloodQ885070
P1476titlePhase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
P478volume100

Reverse relations

cites work (P2860)
Q35125889A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.
Q35628954A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Q38107993ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.
Q35056738ABC transporters: unvalidated therapeutic targets in cancer and the CNS
Q35193725ATP Binding Cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients
Q38234863Acute myeloid leukemia and myelodysplastic syndromes in older adults
Q38026008Acute myeloid leukemia in older adults
Q27851713Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
Q33905670Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan
Q35664332Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial.
Q35038054Cancer stem cells and side population cells in breast cancer and metastasis.
Q36111203Chamaejasmin B exerts anti-MDR effect in vitro and in vivo via initiating mitochondria-dependant intrinsic apoptosis pathway
Q37065843Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
Q41871957Do commonly used clinical trial designs reflect clinical reality?
Q35946969Drug resistance: still a daunting challenge to the successful treatment of AML.
Q37289691Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720.
Q38887070Esters of the marine-derived triterpene sipholenol A reverse P-GP-mediated drug resistance.
Q47140172Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1α, EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes.
Q27851545Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study
Q34786280Free radical theory of autoimmunity
Q84966141Generating inhibitors of P-glycoprotein: where to, now?
Q36873270Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia
Q36020057HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1
Q39655929Image-Based Chemical Screening Identifies Drug Efflux Inhibitors in Lung Cancer Cells
Q60171352Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization f
Q33380148Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
Q34166391Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells
Q24612217Micro-RNAs and copy number changes: new levels of gene regulation in acute myeloid leukemia
Q33758413Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)
Q34255292Molecular pathways: regulation and therapeutic implications of multidrug resistance
Q34052614Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
Q38651372Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly
Q41881090New treatments and strategies in acute myeloid leukemia
Q64108677Novel 3,4-Dihydroisocoumarins Inhibit Human P-gp and BCRP in Multidrug Resistant Tumors and Demonstrate Substrate Inhibition of Yeast Pdr5
Q37495378Novel postremission strategies in adults with acute myeloid leukemia
Q47129596Novel strategies to prevent the development of multidrug resistance (MDR) in cancer.
Q64388331Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells
Q34349313Overcoming drug resistance by regulating nuclear receptors
Q33934534P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA
Q34124919P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808
Q36623275Paclitaxel nanocrystals for overcoming multidrug resistance in cancer
Q37338371Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia
Q35849784Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
Q33750171Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.
Q38769960Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia
Q50673610Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
Q35584427Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity
Q34774854Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance
Q36414444Semi-synthetic ocotillol analogues as selective ABCB1-mediated drug resistance reversal agents.
Q35847482Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222.
Q30497200Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia
Q38233077Strategies for overcoming the blood-brain barrier for the treatment of brain metastases
Q28481389Synthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanisms
Q37199950Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
Q42118010Targeting leukemia stem cells: The new goal of therapy in adult acute myeloid leukemia
Q36680180Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance
Q28535342The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions
Q37289700The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms
Q90113477The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP
Q27014790The clinically relevant pharmacogenomic changes in acute myelogenous leukemia
Q37941758The controversial role of ABC transporters in clinical oncology.
Q37195803The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia
Q37002357Therapeutic implications of leukemic stem cell pathways
Q34597777Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
Q37301691Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.
Q37129807Treatment resistance mechanisms of malignant glioma tumor stem cells
Q33579371Ubc9 expression predicts chemoresistance in breast cancer
Q41889792Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo
Q34360283Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999

Search more.